Tweet this: As drug makers experiment with the use of social media to engage consumers, they are decidedly reluctant to use these tools to bolster their efforts in designing and developing clinical trials, according to a new survey.. For example, while only one in 10 clinical trials run by drug makers have recruited participants through social media channels, the majority have yet to try it. Why? Concerns range from protecting patient privacy to equally sticky issues such as patients who publicly distort adverse event experiences or introduce research bias by sharing treatment information online with others.. “Like it or not, social media communities as a forum for interaction and engagement are here to stay,” says Ken Getz, the director of sponsored research programs at the Tufts University Center for the Study of Drug Development, which queried 17 drug makers and three contract research organizations.. More on this after the jump…